Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DexCom amends joint development agreement with Animas
DexCom said that this revised agreement gives Animas exclusive rights to DexCom CGM technology, now and in the future, for integration into Animas insulin pumps outside the US.
DexCom said that this revised agreement gives Animas exclusive rights to DexCom CGM technology, now and in the future, for integration into Animas insulin pumps outside the US.
This follow-on agreement, which involves technical support for the WebSDM software for use by the FDA Center for Drug Evaluation and Research review community, will help the FDA
The company expects an annualized reduction of $27 million in cash expenditures when changes are completed in the second quarter of 2009. The company remains staffed with 197
In the study, patients receiving oral Xeloda plus oxaliplatin (Xelox) lived for a median of 19 months, while patients receiving Folfox-4 lived for a median of 18.5 months.
Under the terms of the agreement, Abbott will commence a tender offer by January 26, 2009, to purchase all outstanding shares of Advanced Medical Optics (AMO) at $22
This 24-patient two-cohort, five-arm crossover study included administration of open-label oral triazolam and IV sufentanil on days one and two followed by a double-blinded, randomized dosing of a
Anthera’s fewer recurrent acute coronary events with near-term cardiovascular inflammation suppression (Francis) trial is based upon direct feedback from the FDA via the special protocol assessment procedure. The
The company intends to file a motion with the Bankruptcy Court to implement bid procedures for the sale of the company or its assets, following which potential bidders
The study was conducted in normal healthy volunteers with serum uric acid above 5mg/dl. The results of this study demonstrated that single doses of up to 600mg of
The Independent Safety Monitoring Board’s (ISMB) decision is based on safety assessments of the first five patients to complete at least 30 days of follow up following treatment